Literature DB >> 20568970

Cytomegalovirus colitis in patients without inflammatory bowel disease: a single center study.

Chi Hoon Kim1, Sunha Bahng, Ki Joo Kang, Bon-Ho Ku, Young Cheol Jo, Jin Yong Kim, Dong Kyung Chang, Hee Jung Son, Poong-Lyul Rhee, Jae Joon Kim, Jong Chul Rhee, Young-Ho Kim.   

Abstract

OBJECTIVE: Cytomegalovirus (CMV) aggravates preexisting inflammatory bowel disease (IBD), and there are numerous reports of CMV colitis in IBD patients. However, little attention has been paid to CMV colitis in non-IBD patients. The aim was to determine the clinical manifestations, endoscopic appearance, and clinical course of CMV colitis in non-IBD patients.
MATERIAL AND METHODS: We reviewed medical records of patients diagnosed with CMV colitis based on immunohistochemical studies of biopsy specimens or surgical specimens between 1998 and 2009.
RESULTS: The medical records of 43 patients were reviewed. Subjects included individuals with AIDS, and those undergoing chemotherapy, steroid therapy, or transplantation, as well as individuals with other co-morbidities and individuals with no previous illnesses. Frequent symptoms were non-bloody diarrhea, abdominal pain, fever, and hematochezia. Macroscopically normal rectosigmoid mucosa was observed in eight of 21 patients who underwent full-length colonoscopy. Endoscopic findings were varied, and included macroscopically normal (n = 2), colitis alone (n = 12), ulcer alone (n = 5), and ulcer with colitis (n = 22). The ulcer margin was well-circumscribed in 12 of 21 patients. Thirty-six patients were administered antiviral agents and two patients died. All patients who were not treated with an antiviral agent recovered spontaneously while waiting for their biopsy results.
CONCLUSIONS: Colonoscopy is preferred to sigmoidoscopy for diagnosis of CMV colitis. Antiviral therapy should not be mandatory for a subset of patients with CMV colitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20568970     DOI: 10.3109/00365521.2010.499962

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

Review 1.  Host genetic susceptibility, dysbiosis, and viral triggers in inflammatory bowel disease.

Authors:  Lulu Sun; Gerardo M Nava; Thaddeus S Stappenbeck
Journal:  Curr Opin Gastroenterol       Date:  2011-07       Impact factor: 3.287

2.  Eosinophilic enteritis accompanied by cytomegalovirus disease: a case report.

Authors:  Yuichi Yamaga; Masahiro Mizuno; Shunji Okae; Mikako Nio-Tamaoki; Kenji Masuo; Yoko Mashimo-Matsuo; Junya Tanaka; Motoshige Nabeshima
Journal:  BMC Gastroenterol       Date:  2022-04-28       Impact factor: 2.847

3.  Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  Elena Garrido; Elisa Carrera; Rebeca Manzano; Antonio Lopez-Sanroman
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 4.  Gut inflammation and immunity: what is the role of the human gut virome?

Authors:  Alfredo Focà; Maria Carla Liberto; Angela Quirino; Nadia Marascio; Emilia Zicca; Grazia Pavia
Journal:  Mediators Inflamm       Date:  2015-04-07       Impact factor: 4.711

Review 5.  Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review.

Authors:  Chun-Yuan Lee; Yen-Hsu Chen; Po-Liang Lu
Journal:  BMC Infect Dis       Date:  2017-02-01       Impact factor: 3.090

6.  Pancolitis associated with higher mortality risk of cytomegalovirus colitis in patients without inflammatory bowel disease.

Authors:  Puo-Hsien Le; Chia-Jung Kuo; Ren-Chin Wu; Jun-Te Hsu; Ming-Yao Su; Chun-Jung Lin; Cheng-Tang Chiu
Journal:  Ther Clin Risk Manag       Date:  2018-08-20       Impact factor: 2.423

Review 7.  A Rare Case of Ulcerative Colitis with Severe Pneumocystis jirovecii Pneumonia and Cytomegalovirus Colitis: A Case Report and Literature Review.

Authors:  Yusuke Watanabe; Kazunao Hayashi; Shuji Terai
Journal:  Intern Med       Date:  2021-08-06       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.